血小板与慢性阻塞性肺疾病相关研究进展  

Progress in platelets and chronic obstructive pulmonary disease

作　　者：梁乐诗 莫环琦 张弋[1] 梁振宇 许浦生[1] Liang Leshi;Mo Huanqi;Zhang Yi;Liang Zhenyu;Xu Pusheng(Department of Pulmonary and Critical Care Medicine,the Second Affiliated Hospital of Guangzhou Medical University,Guangzhou 510020,China;Guangdong Provincial Hospital of Chinese Medicine,Guangdong 510001,China;Guangzhou Institute of Respiratory Health(National Clinical Research Center for Respiratory Diseases,State Key Lab for Respiratory Diseases),Guangzhou 510120,China)

机构地区：[1]广州医科大学附属第二医院呼吸与危重症医学科,广州510020 [2]广东省中医院胸外科,广州510001 [3]广州呼吸健康研究院,广州510120

出　　处：《中华结核和呼吸杂志》2022年第10期1050-1054,共5页Chinese Journal of Tuberculosis and Respiratory Diseases

基　　金：国家重点研发计划(2017YFC1310600);广东省医学科学技术研究基金项目(C2019006)。

摘　　要：血小板相关病理生理机制及临床研究是目前国内外慢性阻塞性肺疾病(慢阻肺)的研究热点之一, 越来越多证据证明血小板增多症与慢阻肺有关, 血小板活化与慢阻肺相互影响。抗血小板治疗被证实对慢阻肺短期和长期结局都有明显影响。血小板抑制可能成为慢阻肺新的治疗靶点, 抗血小板治疗有望成为慢阻肺经济而有效的治疗方式。本文就血小板与慢阻肺相关研究进展作一综述。Platelets-related pathophysiological mechanism and clinical research is one of the research hot topics in chronic obstructive pulmonary disease(COPD)at home and abroad.Increasing evidence has proved the association between thrombocytosis and COPD.Platelets activation interacts with COPD.Antiplatelet therapy has been shown to have significant effects on both short-term and long-term outcomes in COPD.Platelets inhibition may be an emerging therapeutic target for COPD,and antiplatelet therapy is expected to become an inexpensive and effective treatment for COPD.This article reviewed the research progress in platelets and COPD.

关 键 词：病理生理机制 抗血小板治疗 血小板增多症 血小板活化 慢阻肺 慢性阻塞性肺疾病 血小板抑制 治疗靶点 

分 类 号：R563.9[医药卫生—呼吸系统]